SCHEMBL559382

SCHEMBL559382

Nc1nc2cnccn2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 15/20 0.40
PIK3CD O00329 13/20 0.40
PIK3CB P42338 3/20 0.39
JAK2 O60674 1/20 0.38
PIK3CA P42336 2/20 0.35
PAK4 O96013 2/20 0.35
CSNK1A1 P48729 2/20 0.35
JAK1 P23458 1/20 0.35
AAK1 Q2M2I8 1/20 0.35
PIP4K2C Q8TBX8 1/20 0.35
CSNK1G1 Q9HCP0 1/20 0.35
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
DYRK1A Q13627 2/20 0.32
MAP4K4 O95819 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
GRK5 P34947 1/20 0.32
MAPK8 P45983 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4228752 0.75 BRAF (0.33) KDM4EDYRK1A
SCHEMBL20792879 0.75 DYRK1A (0.31) DYRK1A
SCHEMBL15933473 0.75 DYRK1A (0.31) DYRK1A
SCHEMBL8825850 0.72 PIK3CG (0.36) PIK3CGPIK3CD
SCHEMBL4230547 0.71 KDM4E (0.31) KDM4E
SCHEMBL12963740 0.71 HPGD (0.31)
SCHEMBL3216209 0.70 PIK3CG (0.59) PIK3CGPIK3CDPIK3CBPIK3CAPAK4
SCHEMBL23458573 0.69 DYRK1A (0.45) PIK3CGPIK3CDPIK3CBALDH1A1DYRK1A
SCHEMBL20157092 0.68 ADORA3 (0.47) KDM4ESMN1; SMN2
SCHEMBL2077769 0.68 JAK2 (0.50) PIK3CGPIK3CDPIK3CBJAK2PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041731-B1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORP (US) 2026-02-18 EP claimed
CN-115298177-B Bicyclic amines as CDK2 inhibitors 因赛特公司 2025-01-17 CN claimed
CN-119285947-A Low-temperature curing polyimide precursor solution and preparation method thereof 北京化工大学常州先进材料研究院 2025-01-10 CN claimed
CN-115298177-A Bicyclic amines as CDK2 inhibitors 因赛特公司 2022-11-04 CN claimed
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 EP disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
CN-119998271-A Pyridone compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2025-05-13 CN disclosed
CN-119285947-A Low-temperature curing polyimide precursor solution and preparation method thereof 北京化工大学常州先进材料研究院 2025-01-10 CN disclosed
WO-2024174229-A1 COVALENT BINDING COMPOUNDS AND COMPOSITIONS ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) 2024-08-29 WO disclosed
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2024-08-15 US disclosed
US-20240199651-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-06-20 US disclosed
US-20240182495-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-06-06 US disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
WO-2009131926-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 PIK3CG 1400/4885PIK3CD 1486/4885PIK3CB 1692/4885
US-20240199651-A1 ANTIBACTERIAL COMPOUNDS FDPS, MT-ND4, NDUFS3 PIK3CG 2659/4885PIK3CD 2963/4885PIK3CB 2953/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 PIK3CG 1400/4885PIK3CD 1486/4885PIK3CB 1692/4885
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS PDXK, BTK, TYK2 PIK3CG 244/4885PIK3CD 74/4885PIK3CB 86/4885
US-20240182495-A1 ANTIBACTERIAL COMPOUNDS FDPS, MT-ND4, NDUFS3 PIK3CG 2659/4885PIK3CD 2963/4885PIK3CB 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.